GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curocell Inc (XKRX:372320) » Definitions » Construction In Progress

Curocell (XKRX:372320) Construction In Progress : ₩1,655.63 Mil (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Curocell Construction In Progress?

Curocell's quarterly construction in progress increased from Jun. 2022 (₩0.00 Mil) to Dec. 2022 (₩32,623.39 Mil) but then declined from Dec. 2022 (₩32,623.39 Mil) to Jun. 2023 (₩1,655.63 Mil).

Curocell's annual construction in progress increased from Dec. 2021 (₩2,600.79 Mil) to Dec. 2022 (₩32,623.39 Mil) but then declined from Dec. 2022 (₩32,623.39 Mil) to Dec. 2023 (₩13.95 Mil).


Curocell Construction In Progress Historical Data

The historical data trend for Curocell's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curocell Construction In Progress Chart

Curocell Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Construction In Progress
3,033.73 - 2,600.79 32,623.39 13.95

Curocell Semi-Annual Data
Jun22 Dec22 Jun23 Dec23
Construction In Progress - 32,623.39 1,655.63 13.95

Curocell Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Curocell (XKRX:372320) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
11, Gukjegwahak 16-ro, Yuseong-gu, Daejeon, KOR, 34002
Curocell Inc is engaged in medical and pharmaceutical research and development. The company is into development of CAR-T treatments that enhance the natural function of immune cells to eliminate cancer cells through genetic manipulation of human immune cells.

Curocell (XKRX:372320) Headlines

No Headlines